Clinical Significance of Serum IL-12 Level in Patients with Early Breast Carcinoma and Its Correlation with Other Tumor Markers by Youssef, Samar Samir et al.
 _______________________________________________________________________________________________________________________________ 
  640                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
 
ID Design 2012/DOOEL Skopje 
Open Access Macedonian Journal of Medical Sciences. 2015 Dec 15; 3(4):640-644. 
http://dx.doi.org/10.3889/oamjms.2015.106 
eISSN: 1857-9655 
Clinical Science 
  
 
 
Clinical Significance of Serum IL-12 Level in Patients with Early 
Breast Carcinoma and Its Correlation with Other Tumor Markers 
 
 
 
Samar Samir Youssef
1*
, Manal Moussa Mohammad
2
, Lobna R. Ezz-El-Arab
3
 
 
1
National Research Center, Microbial Biotechnology Department, Cairo, Egypt; 
2
National Research Center, Medical 
Physiology Department, Medical Research Division, Cairo 11331, Egypt; 
3
Faculty of Medicine, Ain Shams University, 
Radiation Oncology and Nuclear Medicine, Cairo, Egypt 
 
 
 
Citation: Youssef SS, Mohammad MM, Ezz-El-Arab LR. 
Clinical Significance of Serum IL-12 Level in Patients with 
Early Breast Carcinoma and Its Correlation with Other 
Tumor Markers. OA Maced J Med Sci. 2015 Dec 15; 
3(4):640-644. http://dx.doi.org/10.3889/oamjms.2015.106 
Key words: Breast cancer; hormone receptor; prognosis;  
tumor markers; IL-12. 
*
Correspondence: Dr. Samar Samir Youssef. National 
Research Center, Microbial Biotechnology Department, El 
Behous st, Dokki. Cairo 12311, Egypt. Phone: 33371362. 
Fax: 33370931. E-Mail: youssefsamar1969@yahoo.com 
Received: 22-Aug-2015; Revised: 02-Oct-2015; 
Accepted: 03-Oct-2015; Online first: 03-Nov-2015 
Copyright: © 2015 Samar Samir Youssef, Manal Moussa 
Mohammad, Lobna R. Ezz-El-Arab. This is an open 
access article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, 
provided the original author and source are credited. 
Competing Interests: The authors have declared that no 
competing interests exist. 
 
 
 
 
 
 
 
Abstract  
AIM: To investigate the diagnostic significance of Interleukin 12 (IL-12) in breast cancer (BC) and 
its correlation with other tumor markers including cancer antigen 15-3 (CA 15-3), carcinoembryonic 
antigen (CEA), matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinases-1 (TIMP-
1), and MMP9/TIMP1 ratio.  
METHODS: Serum levels of IL-12, tumor markers, and hormone receptors were measured in 92 
BC and 56 benign lesion patients versus 40 healthy subjects. Clinical stage, tumor size, lymph 
node metastasis, grade, and histological type were recorded.  
RESULTS: BC patients have lower IL-12, but higher CA 15.3 and CEA than control group. High 
levels of serum IL-12 were associated with lymph node positivity and progesterone receptor 
negativity. IL-12 was significant lower in invasive ductal carcinoma (IDC) compared to non IDC 
histological type. IL-12 was higher in patients with higher stage and grade but the difference was 
not statistically significant.IL-12 correlates negatively with MMP9/TIMP1 ratio.  
CONCLUSION: IL-12 is less specific than CEA for screening early BC, but its correlation with tumor 
aggressiveness and progression markers may have a prognostic value. 
 
 
 
 
 
 
 
Introduction 
 
Breast cancer is reported to occur at a higher 
rate in women of advanced countries than do other 
cancers [1]. The incidence and mortality from BC in 
developing countries are expected to increase in the 
near future due to the trend of living westernization. 
According to Ferly 2008, BC accounts for 38% of all 
new cancer cases in Egypt [2]. In most BC cases, the 
patients neither practice self examination nor have 
detectable symptoms. Therefore, it is very important 
to find markers for early diagnose to reduce sequel 
and mortality. 
The etiology of BC is multifactorial, and its 
clinical course and molecular and pathological 
features are highly diverse [3]. Estrogen receptor 
(ER), progesterone receptor (PgR), and human 
epithelial growth factor receptor 2 (HER2) are 
recognized as common clinical markers for tumor 
growth and progression, and indicators for 
determining appropriate therapy for BC patients [4]. 
Similarly, concentrations of both Matrix 
metalloproteinase-9 (MMP-9) and Tissue inhibitor of 
metalloproteinases-1(TIMP-1) have been suggested 
as useful biomarkers for predicting BC progression 
and thus patient survival [5]. 
Both innate and acquired arms of the immune 
system are believed to play crucial roles in the anti- 
tumor response, and the interaction between host 
immune system and tumor cells has been the subject 
of intense research over the past decades [6, 7]. 
Cytokines are intercellular short-acting soluble 
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mediators produced by immune cells and are involved 
in the pathogenesis of cancer. Changes in cytokine 
levels mediated directly or indirectly by the  tumor are 
important parameters that affect the course of disease 
[3]. 
Interleukin-12 (IL-12) is a cytokine that plays 
an essential role in both innate and adaptive arms of 
immunity [8]. IL-12 is known to play a fundamental 
role in activating anti tumor immunity; it induces T-cell 
differentiation and activates natural killer cells [8]. It is 
also an antiangiogenic agent [9, 10] that enhances 
anti tumor activity in preclinical models [11]. 
Endogenous IL-12 is required for resistance to many 
pathogens and to transplantable and chemically 
induced tumors. In experimental tumor models, 
recombinant IL-12 treatment has a dramatic anti- 
tumor effect on transplantable tumors. It has been 
previously shown that IL-12 also regulates the levels 
of MMP-9 and TIMP-1 in the tumor micro-environment 
of BC model [12]. Nonetheless, studies investigating 
the correlation of IL-12 with MMP9 and TIMP1 in BC 
patients are lacking. 
The studies that evaluated the predictive and 
prognostic significance of serum IL-12 levels in BC 
patients; in addition to its correlation with other 
prognostic markers are few and have conflicting 
results [13-16]. Moreover, studies investigating the 
correlation between IL-12 expression and MMP9 and 
TIMP1 are lacking. Therefore, the aim of this study 
was to evaluate the serum level of IL-12 at different 
stages of BC and its correlation with other prognostic 
tumor markers in BC patients compared to benign 
lesion and healthy subjects. 
 
 
Materials and Methods 
 
Patient characteristics  
The study population included consecutive 92 
women with proved early stage BC, and 56 women 
with benign (B) breast lesions. Control (C) group 
included 40 apparently healthy women with no viral 
infections or other clinical complications. Benign 
lesions were randomly selected in the same time 
period. Serum samples were obtained at baseline, 
none of the patients was pre-treated.  
Breast physical examination was carried out. 
The tumors were graded according to the modified 
Nottingham SBR system [17] and categorized 
according to TNM staging [18]. Tumor assessment 
was done including histopathological grade, lymph 
node status, and hormone receptor (ER, PgR and 
HER2) status.  
IL 12 and  tumor marker detection 
  IL-12 p 40 was measured using sandwich 
enzyme-linked immunosorbent assay (ELISA) kits 
from Boster immunoleader (Boster Biological 
Technology Co., Inc.). ELISA kits purchased from 
Abcom (Cambridge, MA, USA), were used to measure 
serum CEA and CA15-3 protein levels per the 
manufacturer’s instructions. Serum concentrations of 
MMP-9 and TIMP-1 were determined by using human 
MMP-9 and TIMP-1 ELISA kits from RayBiotech 
(Norcross, GA) according to the manufacturer 
protocol. 
 
Hormone receptor immunohistochemistry 
Immunohistochemistry was performed on 
paraffin-embedded tissues sections (3-4 μm-thick) 
using the following primary antibodies: ER-α (clone 
6F11, monoclonal; Novocastra, Newcastle-Upon-
Tyne, UK), PgR (clone PgR636, monoclonal; 
DakoCytomation, Glostrup, Denmark) and HER2 
(A0485, polyclonal; DakoCytomation). 
Diaminobenzidine (Dako) was used as the 
chromogen. ER and PgR expression was considered 
positive when at least 10% of invasive tumoral cells 
exhibited nuclear staining, regardless of intensity. For 
HER2, the immunohistochemical score was assigned 
according to the Herceptest scoring system [19]. 
 
Statistical analysis 
The mean, mean rank and median levels of 
expression of analyzed interleukins were compared 
using Kruskal-Wallis. We used Pearson correlation to 
test the associations between different variables. The 
t test and one-way ANOVA were performed to 
calculate the P value. The threshold value for optimal 
sensitivity and specificity of MMP-9, TIMP-1, MMP-9/ 
TIMP-1 were determined by Receiver Operating 
Characteristics (ROC) curve, which was constructed 
by calculating the true-positive fraction (sensitivity %) 
and false-positive fraction (100- specificity %) of the 
above-mentioned markers at several cut-off points 
[12]. The P values were considered statistically 
significant if P < 0.05.  
 
 
Results 
 
Clinical characteristics of subjects 
All included subjects were females with age 
range 17-67 years, there wasn’t a significant 
difference in the mean age and body mass index 
between BC, and benign lesion patients and control 
subjects (P = 0.143, P = 0.2). Among 92 BC patients, 
64 had positive ER, 56 had positive PgR, 60 had 
positive HER2. 36 were lymph node positive. 
According to their clinical stage, 52 patients were 
stage I and 40 patients were stage II. Regarding 
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grade, there have been 64 grade I, and 28 grade II 
patients. Patients were divided according to the 
histological type of the tumor to invasive ductal 
carcinoma (IDC, n = 64) and non-invasive ductal 
carcinoma (NIDC, n = 28).  
 
Serum levels of IL-12, CEA and CA 
Serum CEA and CA levels were statistically 
significantly lower in control (C) than both benign (B) 
and Breast cancer (BC) subjects as shown in Table 1.  
Table 1: IL-12 and biomarkers serum levels in BC, benign and 
control subjects 
Groups Median of serum values 
 CEA 
(ng/ml) 
CA15-3 
(ng/ml) 
IL-12 
(pg/ml) 
Control (N=40) 0.8250 10.900 170 
Benign (N=56) 0.900 10.450 130 
BC (N=92) 16.00 72.000 53.6 
Significance (P) 0.0001 0.0001 0.0001 
N:number, P: P value 
 
On the contrary, IL-12 serum level was 
significantly higher in control compared to BC and 
benign tumor patients. Table 2 shows that IL-12 has 
similar specificity but 10% less sensitivity than CEA 
and CA. 
Table 2: ROC curve analysis results for comparison of 
diagnostic efficiency of IL-12 compared to CA15-3 and CEA 
  AUC  95% CI (SE) Sensitivity (%) Specificity (%)  
CEA 0.870 0.794 - 0.925 (0.0496) 91.3% 94.1% 
CA15-3 0.873 0.797 - 0.928 (0.0491) 95.7% 97.1% 
IL-12 0.664 0.569 - 0.750 (0.0588) 82.6% 94.9% 
 
 
Correlation of IL-12 and tumor markers with 
patients’ clinical status 
We compared median levels of serum IL-12 
and other tumor markers with the patients’ clinical 
status; the results are shown in Table 3. IL-12 was 
significantly higher in hormone receptor negative, LN 
positive, and NIDC patients. Higher stage and grade 
were associated with higher IL-12 level, but the 
difference was not statistically significant.  
Early stage of BC was found to be 
significantly associated with higher levels of CA15.3, 
MMP9, TIMP1, and MMP9/TIMP1 ratio. Higher MMP9 
expression was significantly associated with LN 
positivity. Higher TIMP1 level was associated with 
positive ER and PgR.  
 
Correlation of IL-12 with other prognostic 
markers in BC patients 
The statistical correlation between serum 
levels of prognostic markers with IL-12 in BC was 
investigated. Results showed statistically significant 
correlation between serum levels of IL-12 with 
MMP/TIMP ratio, CEA cut 5, CEA 15.3=30 in BC 
(table 4).  
Table 3: IL-12, CEA, CA, TIMP1, MMP9 and clinicopathological 
markers  
Parameter  N 
 
IL-12 
Median 
(pg/ml) 
CEA 
Median 
(ng/ml) 
CA15.3 
Median 
(ng/ml) 
MMP9 
Median 
(ng/ml) 
TIMP1 
Median 
(ng/ml) 
MMP9/TIMP1 
ER :  
+ve 
 -ve 
 
64 
28 
 
46.05 
128.8 
 
16.0 
16.0 
 
73.5 
67.0 
 
53.9 
48.6 
 
142.4 
116.8 
 
0.391 
0.404 
P value  0.08 .972 0.265 0.552 0.001* 0.700 
PgR 
+ve 
 -ve 
 
56 
36 
 
41.7 
128.8 
 
15.5 
18.0 
 
69.5 
77.0 
 
53.6 
53. 7 
 
141.5 
121.5 
 
0.394 
0.395 
P value  0.008* 0.328 0.95 0.644 0.024* 0.988 
HER2 
+ve 
-ve 
 
60 
32 
 
50.59 
100.5 
 
16.0 
18.0 
 
67.0 
76.5 
 
54.46 
50.72 
 
141.3 
127.7 
 
0.397 
0.389 
P value  0.053* 0.364 0.836 0.62 0.055 0.84 
LN 
+ve 
-ve 
 
36 
56 
 
133 
36.05 
 
16.0 
16.0 
 
67.0 
73.0 
 
56.25 
47.72 
 
135.7 
136.6 
 
0.352 
0.422 
P value  0.014* 0.828 0.129 0.011* 0.589 0.023* 
Stage 
I 
II 
 
52 
40 
 
50.0 
78.3 
 
17.0 
16.0 
 
77.0 
65.5 
 
58.6 
47.6 
 
140.3 
126.5 
 
0.427 
0.353 
P value  0.879 0.416 0.021* 0.0001* 0.036* 0.013* 
Grade 
Low grade 
High grade 
 
64 
28 
 
51.8 
68.0 
 
16.0 
24.0 
 
67.0 
83.0 
 
49.7 
57.8 
 
136.6 
135.7 
 
0.384 
0.42 
P value  0.251 0.132 0.131 0.098 0.652 0.27 
Histological 
type 
IDC 
NIDC 
 
 
64 
28 
 
 
46.05 
130.24 
 
 
14.5 
20.0 
 
 
66.5 
78.0 
 
 
55.42 
51.02 
 
 
137.1 
132.6 
 
 
0.413 
0.352 
P value  0.019* 0.096 0.414 0.05 0.5 0.059 
Parameter  N 
92 
IL-12 
Median 
(pg/ml) 
CEA 
Median 
(ng/ml) 
CA15.3 
Median 
(ng/ml) 
MMP9 
Median 
(ng/ml) 
TIMP1 
Median 
(ng/ml) 
MMP9/TIMP1 
ER :  
+ve 
 -ve 
 
64 
28 
 
46.05 
128.8 
 
16.0 
16.0 
 
73.5 
67.0 
 
53.9 
48.6 
 
142.4 
116.8 
 
0.391 
0.404 
P value  0.08 .972 0.265 0.552 0.001* 0.700 
PgR 
+ve 
 -ve 
 
56 
36 
 
41.7 
128.8 
 
15.5 
18.0 
 
69.5 
77.0 
 
53.6 
53. 7 
 
141.5 
121.5 
 
0.394 
0.395 
P value  0.008* 0.328 0.95 0.644 0.024* 0.988 
HER2 
+ve 
-ve 
 
60 
32 
 
50.59 
100.5 
 
16.0 
18.0 
 
67.0 
76.5 
 
54.46 
50.72 
 
141.3 
127.7 
 
0.397 
0.389 
P value  0.053* 0.364 0.836 0.62 0.055 0.84 
LN 
+ve 
-ve 
 
36 
56 
 
133 
36.05 
 
16.0 
16.0 
 
67.0 
73.0 
 
56.25 
47.72 
 
135.7 
136.6 
 
0.352 
0.422 
P value  0.014* 0.828 0.129 0.011* 0.589 0.023* 
Stage 
I 
II 
 
52 
40 
 
50.0 
78.3 
 
17.0 
16.0 
 
77.0 
65.5 
 
58.6 
47.6 
 
140.3 
126.5 
 
0.427 
0.353 
P value  0.879 0.416 0.021* 0.0001* 0.036* 0.013* 
Grade 
Low grade 
High grade 
 
64 
28 
 
51.8 
68.0 
 
16.0 
24.0 
 
67.0 
83.0 
 
49.7 
57.8 
 
136.6 
135.7 
 
0.384 
0.42 
P value  0.251 0.132 0.131 0.098 0.652 0.27 
Histological 
type 
IDC 
NIDC 
 
 
64 
28 
 
 
46.05 
130.24 
 
 
14.5 
20.0 
 
 
66.5 
78.0 
 
 
55.42 
51.02 
 
 
137.1 
132.6 
 
 
0.413 
0.352 
P value  0.019* 0.096 0.414 0.05 0.5 0.059 
(*) significant at p < 0.05 
 
 
Discussion 
 
Cytokines play varied roles in cancer 
pathogenesis, with increasing evidence suggesting 
their involvement in tumor initiation, growth and 
metastasis [20]. IL-12 is a proinflammatory cytokine. 
The potent anti tumor activity of IL-12 has been 
demonstrated in many preclinical murine tumor 
models [21-23]. Moreover, an earlier study proved that 
cancer patients with elevated blood concentrations of 
 Youssef et al. Serum IL-12 Level in Patients with Early Breast Carcinoma  
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2015 Dec 15; 3(4):640-644.                                                                                                                                                                        643 
 
IL-12 have a higher survival rate than patients with 
low concentrations [24]. Previous studies investigating 
the clinical significance of serum levels of IL-12 in BC 
are few and showed conflicting results. This study is 
devoted to investigate the clinical significance of IL-12 
expression in BC and to deduce its correlation with 
CA15-3, CEA, MMP9, TIMP1 as breast tumor 
markers. 
Table 4: Association of IL-12 expression with prognostic 
markers of BC  
  TIMP MMP MMP/TIMP CEA cutoff=5 CA15.3=30 
IL2 Pearson Correlation 0.193 -0.192 -0.352 -0.375 -0.362 
Sig. (2-tailed) 0.200 0.201 0.017* 0.010* 0.013* 
N 92 92 92 92 92 
(*) significant at p < 0.05 
 
Results of this study for assessing the role of 
IL-12 in early diagnosis of BC patients by ROC curve 
analysis showed that the highest specificity obtained 
for IL-12 was 82% at cut off 147pg/ml. This sensitivity 
is not efficient for screening for early BC. Moreover, 
IL-12 sensitivity was 10% less that of CEA which is 
the marker commonly used to screen BC, and 
consequently IL-12 is not effective for screening and 
diagnosis of early BC patients.  
Derin et al. [14] and Rao et al. [15] reported 
no significant difference between BC patients and 
healthy control serum IL-12. Our results reported a 
significant deficiency in IL-12 expression in BC 
patients than benign tumor patients than healthy 
subjects, a result that is consistent with Merendino et 
al. [9]. Although our results disagree with Hussein et 
al. [13] and Chavey et al. [18] who reported higher 
levels of IL-12 in BC patients than control subjects, 
this conflict may be attributed to the hormone receptor 
(ER, PgR and HER2) status, since similar to their 
findings, we recorded higher levels in ER, PgR and 
HER2 negative rather than positive patients which 
was statistically significant in PgR. Several reports 
demonstrated direct down regulation of cytokines in 
different organs by ER [25-28] and PR [29-32]. The 
inverse correlation between IL-12 and hormone 
receptors status may reflect the greater 
aggressiveness of this subtype of breast tumors, since 
the use of IL-12 as anti tumor is directed to induce or 
increase hormone sensitivity [33]. 
The correlation between serum level of IL-12 
and clinicopathological parameters in BC patients is 
scarcely discussed and results were controversial. 
The current study revealed that IL-12 serum levels 
were statistically higher in NIDC and LN positive 
compared to IDC and LN negative patients, 
respectively. This indicates that IL-12 may have 
noninvasive prognostic value in BC patients. This is 
consistent with the previous Egyptian study of 
Hussein et al., 2004 and also with that of Rao et al., 
2007 and Chavey et al., 2007. 
Many publications support the link between 
MM9, TIMP-1 and  tumor cell survival demonstrating a 
high statistically significant association between high  
tumor or plasma levels of TIMP-1 and poor cancer 
patient outcome [5, 34, 35]. It was previously shown 
that IL-12 regulates MMP9 and TIMP1 in the tumor 
micro enviroment leading to reduced MMP9 and 
increased TIMP1 levels in IL-12 treated tumors [12]. 
But up to our knowledge, this is the first study 
investigating the correlation between serum levels of 
IL-12 and MMP9, TIMP1 and MMP9/TIMP1 in BC. 
Notably, our result recorded a negative correlation 
between serum level of IL-12 and MMP9/TIMP1 ratio, 
supporting earlier reports and pinpointing the 
importance of monitoring disease progression using 
both immune components and proteolytic markers. 
Similarly, this is the first time to assess, the correlation 
between serum levels of IL-12, CA and CEA in BC 
patients; the statistically significant negative 
correlation reported here confirms the role of IL-12 IL-
12 levels in progression of disease as these markers 
are mainly related to disease progression. 
In conclusion, IL-12 may not be the biomarker 
of choice for diagnosis and screening of early BC, 
nonetheless it should be considered as potential 
prognostic markers, especially in combination with 
other prognostic markers like MMP9, TIMP1, CEA and 
CA in early BC patients. 
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